Prostate cancer: Developing novel approaches to castration-sensitive disease

Area of Science:

• Oncology
• Urology

Background:

• Androgen-deprivation therapy (ADT) is the standard treatment for castration-sensitive prostate cancer (CSPC).
• Disease heterogeneity and limited response duration necessitate alternative and novel therapeutic approaches.

Purpose of the Study:

• To review current and emerging treatment strategies for CSPC.
• To explore the role of combination therapies, immunotherapy, and experimental drugs in CSPC management.

Main Methods:

• Review of current literature on CSPC treatment modalities.
• Analysis of ongoing clinical trials investigating novel agents and combination strategies.
• Discussion of multimodality approaches and precision medicine.

Main Results:

• Combinations of ADT with chemotherapy or novel hormonal therapies show promising results in various CSPC stages.
• Immunotherapy and experimental drugs are under active investigation.
• Multimodality strategies are being explored for early-stage disease to enhance efficacy and response duration.

Conclusions:

• The treatment landscape for CSPC is expanding beyond ADT, incorporating chemotherapy, novel hormonal agents, and immunotherapy.
• Balancing clinical benefits with potential toxicity and quality of life impacts is crucial.
• Precision medicine and robust biomarkers are essential for advancing CSPC treatment.